Published in Br J Haematol on November 01, 1997
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72
Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ (2001) 2.40
Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probe. Blood (1994) 2.24
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A (1999) 2.16
Prognostic factors in metastatic breast cancer. Cancer Clin Trials (1981) 1.96
Genetic predisposition to human lung cancer. Br J Cancer (1986) 1.94
The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer (2005) 1.54
Is high prevalence of Echinococcus multilocularis in wild and domestic animals associated with disease incidence in humans? Emerg Infect Dis (2001) 1.53
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol (1999) 1.47
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45
2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol (1996) 1.43
Life-threatening complications of hepatitis B virus-related polyarteritis nodosa developing despite interferon-alpha2b therapy: successful treatment with a combination of interferon, lamivudine, plasma exchanges and steroids. Clin Rheumatol (2001) 1.42
Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med (2004) 1.42
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer (2006) 1.41
MRI for metallic foreign bodies? Ophthalmology (1999) 1.39
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer (1996) 1.38
Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol (2000) 1.37
Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood (1992) 1.36
Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol (2001) 1.34
Preclinical development of a vaccine 'against smoking'. Onkologie (2002) 1.33
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res (1989) 1.31
Analysis of somatic mutations at human minisatellite loci in tumors and cell lines. Genomics (1989) 1.28
Miniaturization (0.2 g) and evaluation of attachment techniques of telemetry transmitters. J Exp Biol (2005) 1.27
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. Cancer (1987) 1.26
Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells. J Clin Invest (1995) 1.25
Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. J Neurosci (1999) 1.25
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res (2000) 1.24
Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Ann Oncol (1997) 1.22
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). Ann Oncol (1998) 1.20
Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett (2007) 1.17
Alcoholics' deficits in the decoding of emotional facial expression. Alcohol Clin Exp Res (1999) 1.16
Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet (1994) 1.15
Transformations for within-subject designs: a Monte Carlo investigation. Psychol Bull (1993) 1.14
Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. Br J Rheumatol (1994) 1.10
Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol (2008) 1.10
Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatment. Ann Oncol (2006) 1.10
Epstein-Barr virus-associated anaplastic large cell lymphoma in renal transplant patients. Am J Clin Pathol (1992) 1.10
Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death Differ (2007) 1.09
Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland. Oncology (2011) 1.09
Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis (2005) 1.09
Assessment of clonality in human tumors: a review. Cancer Res (1990) 1.08
MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene (2012) 1.08
Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer (2005) 1.07
Pyrimethamine/sulfadoxine resistant falciparum malaria in East Africa. Lancet (1982) 1.06
Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1. Oncogene (2006) 1.06
Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine. Onkologie (2002) 1.05
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer (2008) 1.05
Deficits in recognition of emotional facial expression are still present in alcoholics after mid- to long-term abstinence. J Stud Alcohol (2001) 1.04
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol (1997) 1.04
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets (2010) 1.03
Combined chloroquine/Fansidar-resistant falciparum malaria appears in East Africa. Am J Trop Med Hyg (1983) 1.01
Cataract formation after bone marrow transplantation. Ann Intern Med (1993) 1.00
Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia (2006) 0.99
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene (1998) 0.99
Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol (1996) 0.99
Induction of Bim limits cytokine-mediated prolonged survival of neutrophils. Cell Death Differ (2009) 0.99
Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol (2000) 0.98
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (2000) 0.97
Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos (1996) 0.97
Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study. Palliat Med (2007) 0.97
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer (2010) 0.97
S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. Br J Cancer (2004) 0.97
A myeloperoxidase cDNA clone identifies an EcoRV RFLP. Nucleic Acids Res (1990) 0.97
Subthalamic nucleus stimulation induces deficits in decoding emotional facial expressions in Parkinson's disease. J Neurol Neurosurg Psychiatry (2004) 0.95
Relationship between plasma insulin levels and high density lipoprotein cholesterol levels in healthy men. Diabetologia (1981) 0.95
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol (1989) 0.94
Ifosfamide by continuous infusion to prevent encephalopathy. Lancet (1990) 0.94
Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst (1992) 0.93
Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer (2004) 0.93
DNA synthesis in nucleotide-permeable Escherichia coli cells. VII. Conversion of phi chi-174 DNA to its replicative form. J Mol Biol (1973) 0.93
Implementation of a computer-assisted monitoring system for the detection of adverse drug reactions in gastroenterology. Aliment Pharmacol Ther (2004) 0.93
DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function. Oncogene (2008) 0.93
PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity. Oncogene (2008) 0.93
Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Cancer Res (1999) 0.92
Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochem Biophys Res Commun (2000) 0.92
A simple quantitative HPLC assay for ifosfamide in biological fluids. Biomed Chromatogr (1986) 0.91
A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices. Ann Oncol (1999) 0.91
Immunoscintigraphy with 99mTc labelled F(ab')2 fragments of an anti melanoma monoclonal antibody (225.28S) in patients with metastatic malignant melanoma. Eur J Nucl Med (1987) 0.91
The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1. Leukemia (2010) 0.91
Bioavailability of ifosfamide in patients with bronchial carcinoma. Cancer Chemother Pharmacol (1986) 0.90
The tachykinin NK(1) receptor antagonist SR140333 prevents the increase of nerve growth factor in rat paw skin induced by substance P or neurogenic inflammation. Neuroscience (2000) 0.90
Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol (1997) 0.90
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol (2006) 0.90
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol (1994) 0.89
Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol (1997) 0.89
Impaired emotional facial expression recognition in alcoholism compared with obsessive-compulsive disorder and normal controls. Psychiatry Res (2001) 0.89
Psychogenic purpura, idiopathic thrombocytopenic purpura, and platelet dysfunction in the same patient. J Clin Psychiatry (1986) 0.89
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. Ann Oncol (2001) 0.89